Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, an AI biotech company, raised $311 million in funding at a $2 billion valuation. The company is developing AI-derived drugs currently in clinical trials for skin conditions and weight loss maintenance.
Why it matters
This demonstrates AI's practical application in accelerating drug discovery and bringing new treatments to patients faster than traditional methods.



